Statin Eligibility and Prescribing Across Racial, Ethnic, and Language Groups over the 2013 ACC/AHA Guideline Change: a Retrospective Cohort Analysis from 2009 to 2018

Heintzman, John; Kaufmann, Jorge; Rodríguez, Carlos J.; Lucas, Jennifer; Boston, Dave; April-Sanders, Ayana; Chung-Bridges, Katherine

doi:10.1007/s11606-023-08139-x

Cited by 4 publications

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a large retrospective analysis examined rates of statin eligibility and prescriptions across racial, ethnic, and language groups. 27 After adjusting for gender, age, income status, insurance status, hypertension, hyperlipidemia, obesity, primary care utilization, and Medicaid expansion status Asian, Black, Latino and non-English speaking White patients were more likely to be statin eligible than English speaking White patients. Of these, all but English-speaking Black and Latino patients were more likely to be prescribed statins than Englishspeaking White patients.…”

Section: Statin Eligibilitymentioning

confidence: 99%

“…[24][25][26] This may be in part due to the 2013 ACC/AHA guidelines expanding statin eligibility by recommending the use of the PCE, rather than just LDL-C levels to determine statin eligibility. 27,28 This expansion has been shown to appropriately identify at risk individuals but has also been shown to overestimate ASCVD risk in certain populations. [29][30][31][32][33]…”

Section: Preventative Medication Usementioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics and statin eligibility of patients under 50 with ST‐elevation myocardial infarction

Haq,

Walser‐Kuntz,

Gamam

et al. 2024

Clinical Cardiology

View full text Add to dashboard Cite

AimsThis study seeks to understand the clinical characteristics, risk factors, and statin eligibility of younger adults who present with STEMI.MethodsWe performed a retrospective analysis of a prospective cohort of STEMI patients <50 years. Baseline characteristics, medical history, prior medications, drug use, lipid profiles, cardiovascular risk factors were examined. Ten‐year ASCVD risk was calculated utilizing the Pooled Cohort Equations. Statin eligibility was determined according to the 2019 American College of Cardiology (ACC)/American Heart Association (AHA) and the 2022 US Preventive Services Task Force (USPSTF) guidelines.ResultsSix hundred and thirty‐five individuals were included, the majority were men (82.4%) and white (89%), with a median age was 46.9 [42.0–48.0]. The most prevalent risk factors were current smoking (59%), hyperlipidemia (44%), and hypertension (37%). Drug use was rare (8.3%). Preventative medication use was low, aspirin was the most common (14%), followed by ACE inhibitors/ARBs (12%), statins (11%), and beta‐blockers (9.1%). Mean HDL‐C was low at 36.4 ± 12.0 mg/dL, while mean LDL was unremarkable at 112.4 ± 37.9 mg/dL. According to the 2019 ACC/AHA guidelines, 45.5% were classified as statin recommended, 8.7% were classified as statin considered, and 45.8% were classified as statin not recommended. According to the 2022 USPSTF guidelines, 29% were classified as statin recommended, 12.4% were classified as statin considered, and 58.6% were classified as statin not recommended.ConclusionsYounger adults with STEMI exhibit high rates of tobacco use and low rates of preventative medications use. Approximately half of the cohort did not meet criteria for statin initiation.

show abstract

Section: Statin Eligibilitymentioning

confidence: 99%